ILYX-002 rapidly improves immune-mediated dry eye disease in phase 2 trial
By Justin Cooper Fact checked by Christine Klimanskis, ELS Key takeaways: Dry eye disease associated with systemic autoimmune or inflammatory conditions significantly improved with ILYX-002 after 15 days. ILYX-002 targets…